Benitec Biopharma Stock (NASDAQ:BNTC)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$10.20

52W Range

$2.69 - $12.89

50D Avg

$8.90

200D Avg

$6.62

Market Cap

$103.55M

Avg Vol (3M)

$26.03K

Beta

0.90

Div Yield

-

BNTC Company Profile


Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

16

IPO Date

Jun 24, 2014

Website

BNTC Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 23Jun 22Jun 20
License$75.00K$73.00K-
Grant--$5.00K

Fiscal year ends in Jun 24 | Currency in USD

BNTC Financial Summary


Jun 24Jun 23Jun 22
Revenue-$75.00K$73.00K
Operating Income$-22.49M$-19.08M$-17.85M
Net Income$-22.37M$-19.56M$-18.56M
EBITDA$-22.49M$-18.73M$-17.93M
Basic EPS$-0.01$-14.12$-38.62
Diluted EPS$-0.01$-14.12$-38.62

Fiscal year ends in Jun 24 | Currency in USD

Latest Earnings Call Transcripts


Q3 18Jun 01, 18 | 7:16 PM

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
ONCROncorus, Inc.
VIRIVirios Therapeutics, Inc.
NXTCNextCure, Inc.
APLMApollomics, Inc.
BPTHBio-Path Holdings, Inc.
CAPRCapricor Therapeutics, Inc.
DFFNCervoMed Inc.
LABPLandos Biopharma, Inc.
SGTXSigilon Therapeutics, Inc.
EFTReFFECTOR Therapeutics, Inc.
CBIOGyre Therapeutics, Inc.
ZURAZura Bio Limited
ALRNAileron Therapeutics, Inc.